vorinostat has been researched along with Sarcoma in 9 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In ten sarcoma patients receiving oral Zolinza (400 mg qd) vorinostat concentrations in plasma and peripheral blood mononuclear cells (PBMCs) were quantified using validated LC/MS/MS assays to determine intracellular and extracellular pharmacokinetic data." | 9.24 | Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. ( Burhenne, J; Egerer, G; Haefeli, WE; Heilig, CE; Kasper, B; Leisen, M; Liu, L; Meid, AD; Mikus, G; Schmitt, T, 2017) |
| "A multi-centre, open-label, non-randomised phase II trial to investigate the efficacy and safety of vorinostat in patients with locally advanced or metastatic Soft Tissue Sarcoma failing 1st-line anthracycline-based chemotherapy was initiated." | 9.22 | Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). ( Burhenne, J; Egerer, G; Grünwald, V; Hajda, J; Hartmann, JT; Heilig, CE; Ho, AD; Hüsing, J; Kasper, B; Lehmann, L; Mayer, F; Mayer-Steinacker, R; Mechtersheimer, G; Mikus, G; Ottawa, G; Schmitt, T; Schütte, J, 2016) |
| "Our data strongly indicate the high therapeutic potential of vorinostat in uterine sarcomas." | 7.76 | Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. ( Denk, H; Hrzenjak, A; Kremser, ML; Moinfar, F; Petru, E; Strohmeier, B; Zatloukal, K, 2010) |
| "In ten sarcoma patients receiving oral Zolinza (400 mg qd) vorinostat concentrations in plasma and peripheral blood mononuclear cells (PBMCs) were quantified using validated LC/MS/MS assays to determine intracellular and extracellular pharmacokinetic data." | 5.24 | Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. ( Burhenne, J; Egerer, G; Haefeli, WE; Heilig, CE; Kasper, B; Leisen, M; Liu, L; Meid, AD; Mikus, G; Schmitt, T, 2017) |
| "A multi-centre, open-label, non-randomised phase II trial to investigate the efficacy and safety of vorinostat in patients with locally advanced or metastatic Soft Tissue Sarcoma failing 1st-line anthracycline-based chemotherapy was initiated." | 5.22 | Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). ( Burhenne, J; Egerer, G; Grünwald, V; Hajda, J; Hartmann, JT; Heilig, CE; Ho, AD; Hüsing, J; Kasper, B; Lehmann, L; Mayer, F; Mayer-Steinacker, R; Mechtersheimer, G; Mikus, G; Ottawa, G; Schmitt, T; Schütte, J, 2016) |
| "Our data strongly indicate the high therapeutic potential of vorinostat in uterine sarcomas." | 3.76 | Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. ( Denk, H; Hrzenjak, A; Kremser, ML; Moinfar, F; Petru, E; Strohmeier, B; Zatloukal, K, 2010) |
| "Treatment with Vorinostat/JQ1 inhibited glycolysis/MTOR signaling, activated the clock, and upregulated the UPR and autophagy via inhibition of YAP1/NF-κB." | 1.48 | YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma. ( Babichev, Y; C Brady, D; Chor, S; E Ciotti, G; E Marino, G; Egolf, S; Eisinger-Mathason, TSK; Gladdy, R; Koumenis, C; Leli, NM; Liu, Y; Mancuso, A; Pak, K; Park, PMC; Posimo, JM; Qi, J; Rivera-Reyes, A; Sostre-Colón, J; Tameire, F; Weber, K; Ye, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burhenne, J | 2 |
| Liu, L | 1 |
| Heilig, CE | 2 |
| Meid, AD | 1 |
| Leisen, M | 1 |
| Schmitt, T | 2 |
| Kasper, B | 2 |
| Haefeli, WE | 1 |
| Mikus, G | 2 |
| Egerer, G | 2 |
| Ye, S | 2 |
| Lawlor, MA | 1 |
| Rivera-Reyes, A | 2 |
| Egolf, S | 2 |
| Chor, S | 2 |
| Pak, K | 2 |
| Ciotti, GE | 1 |
| Lee, AC | 1 |
| Marino, GE | 1 |
| Shah, J | 1 |
| Niedzwicki, D | 1 |
| Weber, K | 2 |
| Park, PMC | 2 |
| Alam, MZ | 1 |
| Grazioli, A | 1 |
| Haldar, M | 1 |
| Xu, M | 1 |
| Perry, JA | 1 |
| Qi, J | 2 |
| Eisinger-Mathason, TSK | 2 |
| E Marino, G | 1 |
| E Ciotti, G | 1 |
| Liu, Y | 1 |
| Posimo, JM | 1 |
| Babichev, Y | 1 |
| Sostre-Colón, J | 1 |
| Tameire, F | 1 |
| Leli, NM | 1 |
| Koumenis, C | 1 |
| C Brady, D | 1 |
| Mancuso, A | 1 |
| Gladdy, R | 1 |
| Fröhlich, LF | 1 |
| Mrakovcic, M | 1 |
| Smole, C | 1 |
| Lahiri, P | 1 |
| Zatloukal, K | 2 |
| Nakazawa, MS | 1 |
| Eisinger-Mathason, TS | 1 |
| Sadri, N | 1 |
| Ochocki, JD | 1 |
| Gade, TP | 1 |
| Amin, RK | 1 |
| Simon, MC | 1 |
| Mayer-Steinacker, R | 1 |
| Mayer, F | 1 |
| Grünwald, V | 1 |
| Schütte, J | 1 |
| Hartmann, JT | 1 |
| Hüsing, J | 1 |
| Hajda, J | 1 |
| Ottawa, G | 1 |
| Mechtersheimer, G | 1 |
| Lehmann, L | 1 |
| Ho, AD | 1 |
| Hrzenjak, A | 1 |
| Moinfar, F | 1 |
| Kremser, ML | 1 |
| Strohmeier, B | 1 |
| Petru, E | 1 |
| Denk, H | 1 |
| Oertel, S | 1 |
| Thiemann, M | 1 |
| Richter, K | 1 |
| Weber, KJ | 1 |
| Huber, PE | 1 |
| Perez, RL | 1 |
| Brons, S | 1 |
| Bischof, M | 1 |
| Kulozik, AE | 1 |
| Ehemann, V | 1 |
| Debus, J | 1 |
| Blattmann, C | 1 |
| Xu, S | 1 |
| De Becker, A | 1 |
| De Raeve, H | 1 |
| Van Camp, B | 1 |
| Vanderkerken, K | 1 |
| Van Riet, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Investigate the Efficacy and Tolerability of Vorinostat in Patients Suffering From Advanced, Metastatic Soft Tissue Sarcoma[NCT00918489] | Phase 2 | 40 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for vorinostat and Sarcoma
| Article | Year |
|---|---|
Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Chromatography, Liquid; Epigenesis, Genetic; F | 2017 |
Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Chromatography, Liquid; Epigenesis, Genetic; F | 2017 |
Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Germany; Humans; Hydroxamic Acids; Ma | 2016 |
Vorinostat in refractory soft tissue sarcomas - Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Germany; Humans; Hydroxamic Acids; Ma | 2016 |
7 other studies available for vorinostat and Sarcoma
| Article | Year |
|---|---|
YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
Topics: Adaptor Proteins, Signal Transducing; Angiomotins; Animals; Antineoplastic Agents; Azepines; Cell Cy | 2018 |
YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
Topics: Adaptor Proteins, Signal Transducing; Angiomotins; Animals; Antineoplastic Agents; Azepines; Cell Cy | 2018 |
YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma.
Topics: Activating Transcription Factor 6; Adaptor Proteins, Signal Transducing; Animals; Autophagy; Azepine | 2018 |
YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma.
Topics: Activating Transcription Factor 6; Adaptor Proteins, Signal Transducing; Animals; Autophagy; Azepine | 2018 |
Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
Topics: Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Drug | 2014 |
Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
Topics: Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Drug | 2014 |
Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Calcium Signaling; Cell Line, Tumor; Cell Pro | 2016 |
Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Calcium Signaling; Cell Line, Tumor; Cell Pro | 2016 |
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Fem | 2010 |
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Fem | 2010 |
Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Separation; Chromatin; Combined Modality Th | 2011 |
Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Separation; Chromatin; Combined Modality Th | 2011 |
In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
Topics: Animals; Antigens, CD34; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Transformation, Neoplast | 2012 |
In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.
Topics: Animals; Antigens, CD34; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Transformation, Neoplast | 2012 |